Amanda Boone
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,375 and has fallen 62.7% since, to $513 in 2025. Among family clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$824
- Novo Nordisk$822
- AstraZeneca$509
- Lilly USA, LLC$400
- Biohaven Pharmaceuticals, Inc.$377
- Biohaven Pharmaceutical Holding Company Ltd.$353
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,968100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $824 |
| Novo Nordisk | 63 | $822 |
| AstraZeneca | 25 | $509 |
| Lilly USA, LLC | 22 | $400 |
| Biohaven Pharmaceuticals, Inc. | 33 | $377 |
| Biohaven Pharmaceutical Holding Company Ltd. | 31 | $353 |
| Pfizer | 34 | $346 |
| Abbott | 13 | $234 |
| GSK | 9 | $157 |
| Dexcom, Inc. | 8 | $137 |
| Genentech USA, Inc. | 6 | $114 |
| Amgen | 6 | $94 |
| Shield Therapeutics Inc | 3 | $85 |
| Gilead | 4 | $77 |
| Alkermes, Inc. | 4 | $59 |
| Boehringer Ingelheim | 3 | $53 |
| Scilex Pharmaceuticals Inc. | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Optinose US, Inc. | 2 | $33 |
| Astellas Pharma US Inc | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Novartis | 1 | $19 |
| Braeburn Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Cosette Pharmaceuticals Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
| Indivior Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Eisai Inc. | 1 | $12 |
How this compares
$4,968 in reported general payments places this provider in the 90th percentile of 523 family providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $84,393 |
| MounjaroTirzepatide | 22 | $32,269 |
| TradjentaLinagliptin | 14 | $15,705 |
| Repatha SureclickEvolocumab | 20 | $14,904 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $13,681 |
| Praluent PenAlirocumab | 18 | $11,328 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $8,069 |
| Atorvastatin Calcium | 203 | $1,925 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,840 |
| Ezetimibe | 46 | $1,277 |
| Gabapentin | 66 | $1,233 |
| Omeprazole | 73 | $1,149 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,135 |
| FenofibrateFenofibrate Nanocrystallized | 19 | $944 |
| SynthroidLevothyroxine Sodium | 19 | $898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $822 | $84,39365 claims |
| Lilly USA, LLCMounjaro | $400 | $32,26922 claims |
| Boehringer IngelheimTradjenta | $53 | $15,70514 claims |
| AstraZenecaBreztri Aerosphere | $509 | $13,68118 claims |
| GSKBreo Ellipta | $157 | $8,06911 claims |
| AbbVieSynthroid | $824 | $89819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 523 family providers in Delaware.
Other family in Dover
- Heather GrahamDover$6K
- Shannon CullinDover$5K
- Tina VarugheseDover$3K
- Patricia PowellDover$3K
- Brandi GreggeMiddletown$110K
- Tracy EstesWilmington$59K
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Abby AllenGeorgetown$43K
- Taylor HodgesLewes$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.